Versartis, Inc. (NASDAQ:VSAR) Files An 8-K Results of Operations and Financial Condition

Versartis, Inc. (NASDAQ:VSAR) Files An 8-K Results of Operations and Financial Condition
Item 2.02

Story continues below

Results of Operation and Financial Condition

On July 27, 2017, Versartis, Inc. (the “Company”) issued a press release announcing its financial results for the three- and six-month periods ended June 30, 2017. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 2.02

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished with this Current Report on Form 8-K.

Exhibit

No.

Description

99.1

Press Release, issued by Versartis, Inc. on July 27, 2017.


Versartis, Inc. Exhibit
EX-99.1 2 vsar-ex991_6.htm EX-99.1 Q217 PR vsar-ex991_6.htm Ex 99.1   Versartis Reports Second Quarter 2017 Financial Results Confirms Phase 3 Data Expected Late September Menlo Park,…
To view the full exhibit click here

About Versartis, Inc. (NASDAQ:VSAR)

Versartis, Inc. is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology. The Company’s VRS-317 combines the rhGH amino acid sequence utilized in approved rhGH products with a half-life extension technology, XTEN, to enable less frequent administration. The XTEN technology consists of hydrophilic amino acids added at the genetic level as part of the manufacturing process. The Company’s XTEN is a recombinant polypeptide designed to extend the in vivo half-life of peptides and proteins in a tunable manner. The XTEN sequence consists of hydrophilic amino acids and possesses various additional properties, which are used for the development of protein pharmaceuticals.

An ad to help with our costs